Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means ...

The movement toward measuring patient outcomes resulting from a specific drug therapy, especially in an environment increasingly focused on specialty medicines, has caused researchers to look at different datasets than previously analyzed. Two patient-based datasets in particular come to mind: 1.) electronic health records (EHR), and 2.) claims data. These two data sources will each be suited to ...

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also altered assumptions by business executives about the relationship between recessions and biopharma industry drug demand. This white paper explores three questions about the future relationship of economic recessions to ...

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds empirical light on the effects of potential pharmacist involvement and motivations in brand-to-generic drug substitutions driven by state pharmacy drug product selection (DPS) laws that have to be later reversed as seen in ...

The shift to specialty medicines has opened up for pharma companies a wealth of opportunities in addressing unmet medical needs of patients and improve the cost of care. This shift has also brought significant challenges, especially in the form of pricing and market access in an environment that is becoming increasingly resistant to higher cost drugs. This paper looks at the keys to success on ...

With the US economic recovery, miles driven have also been showing a positive trend lately. What does all this mean? More cars, more miles, and more traffic on the road – all put together – it means more crashes! It’s no surprise that the total number of vehicle crashes has recently shown a halt in a declining trend of several years and is expected to begin to rise again. More crashes imply more ...

Basel will have significant impact on the banking sector. One recent study1 estimated that as the Basel rules are written today; by 2019 the US banks will need about $870 billion of additional Tier 1 capital, $800 billion of short-term liquidity, and about $3.2 trillion of long-term funding, absent any mitigating actions. Closing these gaps will have a substantial impact on profitability. Just ...

The stakeholders and factors that drive the ultimate prescribing of a medication have shifted considerably since the turn of the century. Technological advances (i.e., EMR), cost pressures, quality initiatives, government regulations, and other factors have contributed to the rise and expansion of Integrated Delivery Networks (IDNs). The independence that physicians once experienced in their own ...

The concept of the 'customer-centric business' is pervasive, with companies small and large, across every industry, making efforts to improve customer focus. This is no doubt good as businesses would not exist without customers. However companies run the risk that efforts to increase customer focus become disconnected from business performance. If they do not deliver business value, ...